SWC
JAZZ icon

Spectrum Wealth Counsel’s Jazz Pharmaceuticals JAZZ Stock Holding History

Spectrum Wealth Counsel’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.86K Hold
15
– – ﹤0.01% 289
2024
Q4 		$1.85K Hold
15
– – ﹤0.01% 295
2024
Q3 		$1.67K Buy
+15
New +$1.64K ﹤0.01% 331

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Spectrum Wealth Counsel's JAZZ Position: Q1 2025 in Review

Spectrum Wealth Counsel held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2025 at 15 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #289.

Spectrum Wealth Counsel first reported a position in JAZZ in Q3 2024 and has held it in 3 quarters since. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Spectrum Wealth Counsel held 15 shares of Jazz Pharmaceuticals worth $1.86K as of Q1 2025.
  • Spectrum Wealth Counsel left its Jazz Pharmaceuticals share count unchanged in Q1 2025.
  • Jazz Pharmaceuticals made up ﹤0.01% of Spectrum Wealth Counsel's portfolio in Q1 2025, its #289 holding.
  • Spectrum Wealth Counsel first reported a position in Jazz Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Spectrum Wealth Counsel's 13F filing for Q1 2025, filed 7 May 2025.